Moderna stock steadies after FDA clears mRNA flu vaccine
Published on 08/18/2026 at 11:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna Inc. (US60770K1034) traded at $64.46 on August 17, 2026, while the session range ran from $62.91 to $65.53 and the market value stood at $25.28 billion. The share price also sat 129.48 percent above the level shown in the same market overview, giving investors a fresh read on how sharply the stock has re-rated this year.
FDA clearance takes center stage
The main catalyst is regulatory: a report dated August 14, 2026 said Moderna secured U.S. approval for its first mRNA flu vaccine for adults aged 50 and above. That milestone adds a new commercial product to the pipeline, even as the same report said revenue gains are not expected before 2027.
Market data on August 17, 2026 showed the stock at $64.46, while a separate quote snapshot put it at $64.59 intraday at 2:01 p.m. EDT on August 18, 2026. The two readings point to a tight trading band in the mid-$60s rather than a sharp break in either direction.
Revenue still matters
The latest quarter visible in current market pages was Q2 FY26, with revenue of $143 million and earnings of minus $782 million. One market summary also said the company beat the Q2 FY26 EPS estimate by 9 cents, reporting minus $1.97 versus a minus $2.06 estimate.
That keeps the earnings gap at the center of the story. Moderna's longer-dated analyst view remains cautious, with a consensus price target of $42.13 from 17 analysts, or 34.64 percent below the $64.46 reference price.
What the chart says
The chart is doing some of the work for the bulls. One market page shows a 52-week range of $22.28 to $85.60, so the shares are trading in the upper half of that span after a strong recovery from earlier lows.
In historical context, the same market coverage put the company-wide market cap at $25.28 billion and the stock's previous close at $63.32 on August 17, 2026. The key question for investors is whether the new flu-vaccine approval can narrow the gap between the market's optimism and the still-cautious earnings outlook.
Product and pipeline
Moderna's best-known product line still centers on mRNA vaccines and related medicines, and the newly approved flu shot now adds another commercial reference point for that platform. The approval also broadens the company's case beyond COVID-related demand, which has normalized since the pandemic peak.
Price and setup
Moderna stock last traded at $64.46 on August 17, 2026, with post-market pricing later shown at $64.63. The shares remain heavily influenced by pipeline news, while the current consensus still implies a valuation reset rather than a straight-line climb.
Company
Company: Moderna Inc.
ISIN: US60770K1034
Ticker: MRNA
Exchange: Nasdaq
Price (as of August 17, 2026, 4:00 p.m. ET): $64.46 USD
Market cap: $25.28 billion (as of August 17, 2026)
Sector / Industry: Healthcare / Biotechnology
Index membership: Nasdaq-100
Next earnings date: November 5, 2026
